Satraplatin
From Wikipedia, the free encyclopedia
 |
|
|
Satraplatin
|
|
| Systematic (IUPAC) name | |
| (OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C10H22Cl2N2O4Pt |
| Mol. mass | 500.277 g/mol |
| Synonyms | BMY 45594
BMS 182751 bis-acetatoamminedichlorocyclohexylamine platinum(IV) |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Satraplatin (INN, codenamed JM216) is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration. First mentioned in the medical literature in 1993,[1] satraplatin is the first orally active platinum-based chemotherapeutic drug;[2] other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.
It is made available in the United States jointly by Spectrum Pharmaceuticals and GPC Biotech under the name SPERA (Satraplatin Expanded Rapid Access).
The drug has also been used in the treatment of lung and ovarian cancers. The mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing. [3]
[edit] References
- ^ Kelland LR, Abel G, McKeage MJ, et al (1993). "Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug". Cancer Res 53 (11): 2581–6. PMID 8388318. Free full text
- ^ Choy H, Park C, Yao M (2008). "Current status and future prospects for satraplatin, an oral platinum analogue". Clin Cancer Res 14 (6): 1633–8. doi:. PMID 18347164.
- ^ Satraplatin - Spectrum Pharmaceuticals
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
